Atrial fibrillation (AF) is the most common cardiac arrhythmia and the treatment options include medical treatment and catheter-based or surgical interventions. AF is a major cause of stroke, and its prevalence is increasing. The surgical treatment of AF has been revolutionized over the past 2 decades through surgical innovation and improvements in endoscopic imaging, ablation technology and surgical instrumentation. The Cox-maze (CM) procedure, which was developed by James Cox and introduced clinically in 1987, is a procedure in which multiple incisions are created in both the left and the right atria to eliminate AF while allowing the sinus impulse to reach the atrioventricular node. This procedure became the gold standard for the surgical treatment of AF. Its latest iteration is termed the CM IV and was introduced in 2002. The CM IV replaced the previous cutand-sew method (CM III) by replacing most of the incisions with a combination of bipolar radiofrequency and cryoablation. The use of ablation technologies, made the CM IV technically easier, faster and more amenable to minimally invasive approaches. The aims of this article are to review the indications and preoperative planning for the CM IV, to describe the operative technique and to review the literature including comparisons of the CM IV with the previous cut-and-sew method. Finally, this review explores future directions for the surgical treatment of patients with AF.
INTRODUCTION
The first experimental surgical therapy for atrial fibrillation (AF) was developed in 1980. Several procedures were developed, including the left atrial isolation [1] [2] [3] , the Guiraudon corridor technique [4] and the atrial transection procedure [5] . However, those procedures were abandoned due to their inability to prevent AF and restore normal sinus rhythm.
Cox et al. [6] formulated the Cox-maze (CM) procedure and first performed it on a patient at Barnes Hospital in St. Louis in September 1987. This technique involved making a myriad of left and right atrial incisions that formed a set of scars which isolated the pulmonary veins and posterior left atrium and also theoretically interrupted macrore-entrant circuits thought to be responsible for AF. The initial procedure, the CM I, resulted in occasional left atrial dysfunction and a high incidence of pacemaker implantation due to the inability to generate an adequate sinus node response to exercise and other forms of stress [7] . A second iteration, the CM II, preserved normal sinus node function. The left atrial roof transverse atriotomy was relocated to the posterior wall to enhance intra-atrial conduction [7] . The CM III placed the septal incision posterior to the superior vena cava orifice ( Fig. 1) , enhancing exposure of the left atrium, improving long-term atrial transport and sinus node function, decreasing the need for pacemaker implantation and reducing the recurrence of atrial tachyarrhythmias (ATAs) [7] . The CM III proved to be effective and became the gold standard for surgical treatment of AF [8] . Cox et al. [9] reported success rates in nearly 95% of patients at 10 years. Schaff et al. [10] from the Mayo Clinic reported the safety and efficacy of the CM III at their institution and showed an early operative mortality rate of 1.4% with a 3.2% incidence of postoperative pacemaker implantation.
Despite its efficacy, the CM III was not widely performed because of its complexity and technical difficulty. Modern ablation devices transformed the CM III into an easier, shorter and less invasive procedure, which has been termed the CM IV, the current iteration of the CM. Several technologies have been used for surgical ablation to replace the surgical incisions, with varying results. Cryoablation and bipolar radiofrequency (RF) devices have been shown to be the most effective and are the ablation technologies used for the CM IV [11] .
Task Force on Catheter and Surgical Ablation European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines [12] : (i) all symptomatic patients undergoing other cardiac surgical procedure; (ii) selected asymptomatic patients undergoing cardiac surgery in which the ablation can be performed with minimal additional risk in experienced centres and (iii) standalone surgical ablation for symptomatic patients with AF who have failed medical management and prefer a surgical approach, have recurrent AF after catheter ablation or are not candidates for catheter ablation. Recently, additional indications for surgery at the authors' institution are (i) AF patients at high risk for stroke, such as patients with persistent AF and a CHADS2 score > _2, who develop a contraindication to long-term anticoagulation and (ii) high-risk patients with persistent AF who have had a cerebrovascular event while appropriately anticoagulated [13] .
Recently, Badhwar et al. [14] published a new set of clinical practice guidelines from the Society of Thoracic Surgeons (STS), which include 8 recommendations regarding the surgical treatment of AF. According to the new guidelines, surgical ablation for AF can be performed without additional operative risk of mortality or major morbidity and is recommended at the time of concomitant cardiac surgery to restore sinus rhythm (Class I, Level B non-randomized). Surgical ablation is reasonable as a primary stand-alone procedure for symptomatic AF in the absence of structural heart disease when it is refractory to other therapies (Class IIA, Level B non-randomized). Pulmonary vein isolation alone is not recommended as surgical ablation, however, for symptomatic AF in the setting of left atrial enlargement (> _4.5 cm) or more than moderate mitral regurgitation (Class III no benefit, Level C expert opinion). The left atrial appendage (LAA) excision or exclusion is reasonable for longitudinal thromboembolic morbidity prevention in conjunction with surgical ablation for AF (Class IIA, Level C limited data) or at the time of concomitant cardiac operations in patients with AF (Class IIA, Level C expert opinion). Finally, multidisciplinary heart team assessment, treatment planning and long-term follow-up are recommended as useful and beneficial to optimize patient outcomes in the treatment of AF (Class I, Level C expert opinion) [14] .
The ESC released guidelines for treatment of AF in 2016, which were endorsed by the EACTS. They recommend concomitant surgical ablation for patients with symptomatic AF undergoing open-heart surgery guided by patient choice and a heart team approach (Class IIA, Level A), with consideration of surgical LAA exclusion in selected patients (Class IIb, Level C) [15] . Stand-alone surgical ablation is recommended as an option guided by patient preference and a heart team approach for patients with symptomatic AF refractory to at least 2 antiarrhythmic drugs and/or catheter ablation (Class IIa, Level C) [15] . Rate control and hybrid ablation are other reasonable options in this situation.
The COX-MAZE IV: SURGICAL TECHNIQUE
The CM IV replicates the CM III lesion set using bipolar RF energy and cryoablation to replace most of the incisions of the cut-andsew CM III [16] . Clinical results have shown that the CM IV achieves the high success rate of the CM III while significantly reducing operative time and lowering complication rates [17] .
The CM IV can be performed via a sternotomy or a minimally invasive right minithoracotomy (RMT). The selection of a minimally invasive approach as opposed to a standard surgical approach should be based on the presence of concomitant cardiac pathology, patient-specific anatomic characteristics and the experience of the operating surgeon [13] . Our group at Washington University favours a minimally invasive RMT to perform a full biatrial CM IV in patients undergoing stand-alone AF ablation or as a concomitant procedure to mitral or tricuspid valve surgery. On the other hand, we reserve a median sternotomy for patients with severe peripheral vascular disease that precludes femoral cannulation for cardiopulmonary bypass, a history of previous right thoracotomy, severe left ventricular dysfunction, chest wall deformity such as pectus excavatum [18] or when CM IV is combined with other concomitant procedures such as aortic valve replacement and coronary artery bypass grafting [13] . Patients who are in AF at the time of surgery and have no intracardiac thrombosis on intraoperative transoesophageal echocardiogram are electrically cardioverted and started on intravenous amiodarone. Pacing thresholds are measured from each pulmonary vein [19] .
MEDIAN STERNOTOMY APPROACH
Intrathoracic access is obtained through a median sternotomy in a standard fashion. The superior vena cava and the inferior vena cava are dissected, and bicaval cannulation is performed. After the initiation of normothermic cardiopulmonary bypass, both sets of pulmonary veins are then bluntly dissected, mobilized and encircled with umbilical tapes [19] . As mentioned earlier, before proceeding to the next step of the operation, attempts should be made to achieve normal sinus rhythm.
Pacing thresholds are measured from each pulmonary vein. Using bipolar clamps, we then isolate a cuff of atrial tissue surrounding the right and the left pulmonary veins. Isolation is confirmed by documenting exit block from all pulmonary veins [19] . To perform the right atrial lesion set, the patient is then cooled to 34 C. Lesions from RA lesion set are performed on the beating heart ( Fig. 2A) . To do this, a small purse-string suture is placed at the base of the right atrial appendage that is wide enough to accommodate 1 jaw of the bipolar RF ablation clamp. An ablation lesion is created along the free wall of the right atrium through the purse string down the aortic side of the right atrial appendage [19] . A vertical right atriotomy is made extending from the intra-atrial septum up towards the atrioventricular groove near the free margin of the heart (at least 2 cm from the free wall ablation). From the inferior aspect of the incision, the RF ablation clamp is used to create ablation lines up to the superior vena cava and down towards the inferior vena cava. A linear cryoprobe is used to create an endocardial ablation line from the superior aspect of this atriotomy down onto the tricuspid annulus at the 2 o'clock position. All cryoablations are performed for 3 min at a temperature below -60 C. The linear cryoprobe is then inserted through the previously placed purse-string suture, and an endocardial ablation line is created down to the tricuspid annulus at the 10 o'clock position [19] . The 10 o'clock position could be omitted if the patients have small right atrium and have no tricuspid regurgitation.
Next, the left atrial lesion set is performed on the arrested heart after aortic cross-clamping (Fig. 2B) . The heart is retracted, and the LAA is exposed and amputated. Through the amputated appendage, the bipolar RF clamp is used to create a connecting lesion into the left inferior or superior pulmonary vein, whichever is easier [19] . The LAA is then oversewn in 2 layers with a running polypropylene suture. The coronary sinus is marked with methylene blue between the right and the left coronary circulations. A standard left atriotomy is then performed, and the bipolar clamp is used to create 'roof' and 'floor' lesions from the superior and inferior aspects of the atriotomy to the left superior and inferior pulmonary veins, respectively. The RF ablation clamp is also used to create an ablation from the inferior margin of the atriotomy towards the mitral annulus and across the coronary sinus, taking care to avoid the coronary arteries. As the RF bipolar clamp cannot reach the annulus itself, a bell-shaped cryoprobe is used to make an endocardial lesion to the mitral annulus at the end of the mitral isthmus lesion. To complete the left atrial isthmus ablation, an epicardial cryoablation is performed over the coronary sinus in line with the endocardial lesion (Figs 2 and 3) . It is possible to create the CM IV ablation lines with only cryoablation, and many expert arrhythmia surgeons use this approach. Our centre uses bipolar RF for most ablation lines and cryoablation near the atrioventricular groove, because cryoablation alone requires significantly more time for completion of the lesion set. We do not recommend attempting to produce the CM IV lesion set using bipolar or unipolar RF alone, as this is infeasible and unsafe near the atrioventricular groove. Additionally, cryoablation is ideal over annular tissue, because it preserves the fibrous skeleton of the heart, therefore maintaining valve competency [19] . The atriotomy is then closed with a running polypropylene suture. The patient is weaned from cardiopulmonary bypass and the sternotomy closed in a standard fashion.
RIGHT MINITHORACOTOMY APPROACH
The patient is positioned supine, anaesthetized and intubated with a double-lumen endotracheal tube that is used to allow for right lung deflation. The right chest is elevated to a 30-45 angle. Femoral cannulation for cardiopulmonary bypass is obtained. A 5-6-cm minithoracotomy is performed over the fourth intercostal space lateral to the nipple in the midaxillary line in men; a submammary incision is used in women (Fig. 4) . A soft tissue retractor is used to improve visualization. Rib spreading is avoided to reduce postoperative pain. A Blake drain is placed through the lateral chest wall and positioned in the posterior right pleural space. Carbon dioxide is infused through this drain to prevent air embolism. After the pericardium is opened, a 5-mm thoracoscope is placed through a port in the fifth intercostal space below the incision near the posterior axillary line [18] .
An illustrated description of this minimally invasive RMT approach is available [18, 20] . Furthermore, a video is provided in the online supplementary material [20] . While there are several differences between the median sternotomy and minimally invasive RMT approaches, the lesion set in the RMT approach remains the same. The right atrial lesion set has been modified with replacement of the atriotomy with a line of bipolar RF ablation, whereas the other right atrial lesions are performed through 3 purse-string sutures. The left atrial lesion set is identical with 2 exceptions. Left pulmonary vein isolation is achieved by sequential endocardial cryoablation connecting the superior and inferior connecting box lesions behind the left pulmonary veins, along the lateral ridge. Finally, exclusion of the LAA in the RMT approach is achieved by oversewing it endocardially in 2 layers as opposed to epicardial amputation, as in the median sternotomy approach (Figs 5 and 6 ).
COX-MAZE IV SURGICAL RESULTS
The CM III had excellent success rates for the treatment of AF [21] . Gaynor et al. [22] examined the outcomes of 198 patients who underwent the CM III. Their study showed a 96.6% freedom from symptomatic AF at 5.4 years and no difference in recurrence when comparing patients who received a stand-alone CM III versus patients who received a concomitant procedure (95.9% vs 97.5%, P = 0.64) [21] . However, very few of these patients had prolonged monitoring or even follow-up electrocardiograms. Most of the patients only had telephone follow-up.
The results from patients who underwent the CM IV also have been very encouraging. In a prospective, single-centre study, 91% of patients at 6-month follow-up were free from AF [22] . The CM IV procedure had significantly shorter mean aortic cross-clamp time for a lone CM from 93 ± 34 min for the CM III to 47 ± 26 min for the CM IV (P < 0.001) [22] . A propensity analysis performed by Lall et al. [17] showed no significant difference in freedom from AF at 3, 6 and 12 months postoperatively between appropriately matched patients undergoing either the CM III or the CM IV. A more recent prospective cohort study in 100 patients who underwent a stand-alone CM IV demonstrated postoperative freedom from AF at 93%, 90% and 90% at 3, 6 or 12 months, respectively [16] . A report of over 2 decades of experience by Weimar et al. [23] with both the CM III and the CM IV showed no difference in freedom from AF and a significantly decreased major complication rate. This was despite the fact that the recent cohort had more patients with long-standing persistent AF and much more intensive follow-up with the majority of patients having at least 24-h Holter monitoring.
A recent report of our CM IV experience reviewed 576 consecutive patients who underwent the CM IV between January 2002 and September 2014. Most patients were followed up with prolonged Holter monitoring. Twelve-month freedom from AF was 93%, with 85% of patients free from all antiarrhythmic drugs (AADs), while 5-year freedom from AF was 78%, with 66% of patients also free from all AADs. When comparing patients with paroxysmal AF to patients with persistent AF, freedom from AF on and off AADs was not significantly different at any time point [24] . These 5-year results are similar to those reported by Ad et al. [25] from INOVA Fairfax in Virginia.
The CM has been successful in reducing the incidence of stroke. In a report by Pet et al. [26] , 57 of 433 (13%) patients had experienced a preoperative neurological event. However, there were only 6 postoperative neurological events during long-term follow-up in this cohort (mean 6.6 ± 5.0 years). The long-term stroke rate after the CM has been 0.2% per year, despite the fact that the great majority of patients had discontinued AADs [26] .
AF is frequently coincident with other cardiac diseases, and the CM is commonly used as a concomitant procedure [27] . In patients undergoing mitral valve surgery, studies have demonstrated similar arrhythmia recurrence rates in patients with lone AF who have undergone stand-alone surgical ablation compared to those with AF and mitral regurgitation who underwent concomitant mitral procedures [28] . Specifically, freedom from AF and AADs at 12 and 24 months were nearly the same between the 2 groups (73% vs 76% at 12 months; 77% vs 78% at 24 months) [29] . Gillinov et al. [30] conducted a prospective, randomized controlled trial performed at 20 centres in the Cardiothoracic Surgical Trials Network (CTSN) comparing patients with persistent or long-standing persistent AF who also had mitral valve disease requiring surgical intervention undergoing surgical ablation (pulmonary vein isolation or biatrial maze) or no ablation (control group). Their results showed that more patients in the ablation group than in the control group were free from AF at both 6 and 12 months (63.2% vs 29.4%, P < 0.001). Ablation was associated with more implantations of a permanent pacemaker [30] . This study also demonstrated that surgical ablation did not add to postoperative morbidity or mortality, when compared with the control group who underwent the mitral procedure alone.
Henn et al. [31] also compared outcomes between patients undergoing stand-alone CM IV to those undergoing surgical ablation and concomitant aortic valve replacement and demonstrated that a CM IV with concomitant aortic valve replacement was as effective as a stand-alone CM IV in treating AF, even in an older population with more comorbidities. Schill et al. [32] reviewed outcomes of patients with AF undergoing left or biatrial CM IV and coronary bypass grafting between 2002 and 2015 and showed excellent results in freedom from all ATAs at 1-5 years with low operative mortality (freedom from ATA at 1 year in the CM IV group was 98%, with 88% off AADs and 70% free from ATAs and AADs at 5 years).
The RMT approach to the CM IV has reduced operative morbidity and length of time spent in the intensive care unit and hospital with continued excellent outcomes. Lawrance et al. [33] performed a retrospective review of 365 patients undergoing the CM IV procedure with or without mitral valve surgery. They found that overall freedom from ATAs and AADs among the patients who underwent the CM IV through a sternotomy approach compared with the RMT approach at 2-year follow-up was 79% and 74%, respectively. There were no significant differences in freedom from ATAs and AADs between the 2 approaches at any examined time point except at 6 months, when the RMT approach showed greater freedom from ATAs off AADs (86% vs 75%, respectively; P = 0.04). Major complications were significantly lower overall in the RMT group (6% vs 13%, P = 0.04). Median lengths of intensive care unit and hospital stay were significantly reduced in the RMT group compared with the median sternotomy group (7 days vs 9 days, P < 0.001 and 2 days vs 3 days, P < 0.004) [33] .
CONCLUSION
In the 3 decades since the initial CM procedure was carried out in 1987, surgical treatment for patients with AF has seen extensive advances. The CM technique remains the mainstay of such therapy. The development of ablation technologies over the past 2 decades has dramatically changed the field of AF surgery. The replacement of surgical incisions with transmural and continuous ablation lines (CM IV) has transformed a complex, technically demanding procedure into one accessible to the majority of cardiac surgeons. More importantly, these new ablation technologies have facilitated minimally invasive approaches. The development of a minimally invasive CM IV has lessened the cardiopulmonary bypass time, cross-clamp time, operative risk and overall morbidity while maintaining its efficacy. There has been a dramatic increase in the number of patients receiving surgical ablation particularly in the setting of concomitant cardiac surgery. However, there are still a significant number of patients with AF undergoing other cardiac operations still are not receiving treatment [34] . Our major focus should be on patient and surgeon education to encourage more aggressive treatment of concomitant AF [35] . As we learn more about the mechanisms of AF and develop improved preoperative diagnostic technologies capable of precisely identifying mechanisms, it may become possible to tailor specific lesion sets and ablation modalities to individual patients, making the surgical treatment of AF more effective and available to an even larger population of patients.
